As direct administration of type I IFN preparations used to limit the infection can produce some negative effects, a new strategy was proposed that involves activation of the interferon-stimulated genes (ISGs) encoding, in particular, IFN-induced transmembrane proteins (IFITMs) and cholesterol 25-hydroxylase (CH25H) [87]. The gene discussed is CH25H; the disease is infection.